Meta-analysis of associations between telomere length and colorectal cancer survival from observational studies

Wei Wang1,*, Lei Zheng2,*, Ning Zhou1,*, Na Li1, Gilisihan Bulibu1, Chunlei Xu1, Yi Zhang3 and Yong Tang1

1Department of Digestive Internal Medicine, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xin Jiang Province, China
2Department of Endocrinology, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China
3Department of Pharmacy, The First People's Hospital of Jiashan, Jiashan County, Jiaxing City, Zhejiang Province, China
*Authors contributed equally to this work
Correspondence to: Yong Tang, email: yongtang_vip@126.com
Yi Zhang, email: flowerier123@126.com
Keywords: colorectal cancer, telomere length, meta-analysis, survival
Received: June 02, 2017    Accepted: July 25, 2017    Published: August 07, 2017

ABSTRACT

Background: Telomere length (TL) has been reported to be associated with the risk and survival of several cancers. But it is unclear for the prognostic role of TL in colorectal cancer (CRC).

Materials and Methods: Relevant citations were searched and identified using several major online databases through April 2017 which investigated associations between TL and CRC prognosis. We combined summary estimates using hazard ratios (HRs) with 95% confidence interval (CI), which were pooled using a random-effects model. Overall survival (OS) was set as the primary outcome of interest.

Results: There are 8 cohort studies encompassing 1622 patients included in the meta-analysis. Pooled estimate indicated that long TL was not significantly associated with patient OS (HR 1.26, 95% CI, 0.76 to 2.08). When we conducted subgroup analyses based on baseline characteristics, we found that long TL (versus short TL) was significantly associated with poor OS in studies conducted in Europe (n = 4, HR 2.73, 95% CI, 1.65 to 4.52, I² = 0), using Southern blot to measure TL (n = 3, HR 2.93, 95% CI, 1.69 to 5.10, I² = 0) and patients’ age more than 60 years (n = 3, HR 2.65, 95% CI, 1.22 to 5.76, I² = 0). We found no significant associations between TL and patient disease-free, recurrence-free or progression-free survival (HR 1.19, 95% CI, 0.45 to 3.15).

Conclusions: Current evidence did not provide solid indication that long TL is significantly associated with improved or poor survival for patients with CRC. Further large sample size prospective cohort studies are warranted to determine the true relationship for specific patients.

INTRODUCTION

As a critical structure with numerous DNA sequences of TTAGGG tandem repeats located at the end of linear chromosomes in eukaryote cells, telomere has reported to plays an important role in the protection of genomic instability and DNA degradation [1, 2]. The persistent cell proliferation makes telomere shorten year by year, and meanwhile telomerase activity decreases gradually. The chromosome instability resulting from abnormal alteration of telomere length (TL) may lead to cancer occurrence [3].

The associations between TL and cancer risk, mortality and progression have been reported in numerous studies with controversial results [4–14]. Svenson et al. found that TL was shorter in tumor tissues than the adjacent non-tumorous tissues [15]. Moreover, studies
in a number of malignancies have showed that abnormal alternation of TL in peripheral blood leukocytes is significantly correlated with the mortality and progression of cancer patients, such as breast cancer, prostate cancer, gastric cancer and non-small cell lung cancer [16–19], the prognostic value of TL for colorectal cancer (CRC) has not been fully determined.

In a meta-analysis conducted by Zhang et al. [20], they found that short telomeres were associated with increased CRC mortality, which was also reported by Jia et al [21]. However, due to the small sample size and great heterogeneity among studies in those two studies, we updated the systematic review and meta-analysis to reevaluate the prognostic significance of TL in CRC.

RESULTS

Description of the search and selection of studies

There were a total of 1119 citations identified for eligibility through database search. After exclusion of duplicate publications, screening of the titles or abstracts, there remained 43 citations for full text review. When excluding the studies unsatisfied for the inclusion criteria, we finally enrolled a total of 8 cohort studies encompassing 1622 patients with a median sample size of 131 (range 57 to 571) for this meta-analysis [22–29]. Data on OS and disease-free survival (DFS)/recurrence-free survival (RFS)/progression-free survival (PFS) were available from 7 and 5 studies, respectively (Figure 1).

Study characteristics

The basic elements of all the included studies are presented in Table 1. They were all published in English peer-reviewed journals between 2004 and 2016. Five of 8 of the included studies were conducted in Europe, the other three were in USA, Australia and China, respectively. The sample origins were from peripheral leukocytes in two studies [23, 28] while others were from tumor tissues [22, 24–27, 29]. Eight studies investigated I-IV stage CRC patients and only one of them involved stage IV patients [29]. Five studies used qPCR to measure TL while three used Southern blot. The Newcastle-Ottawa scale (NOS) score of methodological quality assessment ranged from 6 to 8 with 5 studies gaining a score of 7 or above (Table 1).

Telomere length and colorectal cancer survival

Overall survival

Pooled estimate indicated that long TL was not significantly associated with patient OS (hazard ratio [HR] 1.26, 95% confidence interval [CI], 0.76 to 2.08) (Figure 2) and significant inter-study heterogeneity ($I^2 = 82.7\%$, $P < 0.001$) was noted. When we conducted subgroup analyses based on baseline characteristics (Table 2), we found that long TL (versus short TL) was significantly associated with poor OS in studies conducted in Europe ($n = 4$, HR 2.73, 95% CI, 1.65 to 4.52), using Southern blot to measure TL ($n = 3$, HR 2.93, 95% CI, 1.69 to 4.89).
### Table 1: Study features of included studies investigating the survival outcomes of telomere length for colorectal cancer patients

<table>
<thead>
<tr>
<th>Author</th>
<th>Country</th>
<th>Sample origin</th>
<th>Sample size</th>
<th>Mean/median age(ys)</th>
<th>Tumor stage</th>
<th>Treatment regimen</th>
<th>Assay/detection method</th>
<th>Cut-off</th>
<th>Follow up period (months)</th>
<th>Outcome reported</th>
<th>Adjustment factors</th>
<th>Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Svenson, 2016</td>
<td>Sweden</td>
<td>Peripheral leukocytes</td>
<td>130</td>
<td>Mean 70</td>
<td>I-IV</td>
<td>Surgery</td>
<td>qPCR</td>
<td>NR</td>
<td>Median 202 months.</td>
<td>OS</td>
<td>Age, lymphocyte tumor infiltration, and metastatic status</td>
<td>6</td>
</tr>
<tr>
<td>Suraweera, 2016</td>
<td>Australia</td>
<td>Tumor tissue</td>
<td>419</td>
<td>Median 70 (30 to 92)</td>
<td>I-IV</td>
<td>Adjuvant treatment</td>
<td>qPCR</td>
<td>NR</td>
<td>Median OS 5.2, PFS 41.6</td>
<td>OS, DFS</td>
<td>Gender, age, tumor site, stage, differentiation</td>
<td>7</td>
</tr>
<tr>
<td>Fernandez-Marcelo, 2016</td>
<td>Spain</td>
<td>Tumor tissue</td>
<td>132</td>
<td>Median 71</td>
<td>Dukes Stage A-D</td>
<td>Surgery</td>
<td>qPCR</td>
<td>6.35 kb</td>
<td>Median 60 (1–110)</td>
<td>DFS</td>
<td>Gender, age, tumor location, Dukes stage</td>
<td>7</td>
</tr>
<tr>
<td>Augustine, 2015</td>
<td>USA</td>
<td>Tumor tissue</td>
<td>75</td>
<td>Median 60 (34–93)</td>
<td>IV</td>
<td>EGFR inhibitors treatment</td>
<td>qPCR</td>
<td>Median length</td>
<td>NR</td>
<td>OS, DFS</td>
<td>Age, gender, and race.</td>
<td>6</td>
</tr>
<tr>
<td>Chen, 2014</td>
<td>China</td>
<td>Peripheral leukocytes</td>
<td>571</td>
<td>60</td>
<td>I-IV</td>
<td>Surgery+adjuvant chemotherapy</td>
<td>qPCR</td>
<td>0.704</td>
<td>Median 28 (6–60)</td>
<td>OS, RFS</td>
<td>Age, sex, tumor location</td>
<td>8</td>
</tr>
<tr>
<td>Valls, 2011</td>
<td>Spain</td>
<td>Tumor tissue</td>
<td>147</td>
<td>NR</td>
<td>I-IV</td>
<td>Adjuvant therapy</td>
<td>Southern blot</td>
<td>1</td>
<td>Mean 45</td>
<td>OS</td>
<td>Age, gender, N classification, TNM classification, tumor site, tumor histology, adjuvant therapy</td>
<td>7</td>
</tr>
<tr>
<td>Garcia-Aranda, 2006</td>
<td>Spain</td>
<td>Tumor tissue</td>
<td>91</td>
<td>Average 68.60</td>
<td>I-IV</td>
<td>Adjuvant therapy</td>
<td>Southern blot</td>
<td>Mean length</td>
<td>Median 43.86 (1–77)</td>
<td>DFS</td>
<td>Gender, age, Dukes stage, tumor location, and differentiation grade of tumors</td>
<td>6</td>
</tr>
<tr>
<td>Gertler, 2004</td>
<td>Germany</td>
<td>Tumor tissue</td>
<td>57</td>
<td>Mean 64.6</td>
<td>I-IV</td>
<td>Adjuvant radiochemotherapy</td>
<td>Southern blot</td>
<td>0.9</td>
<td>Median 75.5 (52 to 87)</td>
<td>OS</td>
<td>Tumor site, histologic grade, sex, and age, depth of tumor invasion (pT), lymph node status, and lymphatic invasion and hTERT expression</td>
<td>8</td>
</tr>
</tbody>
</table>

Abbreviations: DFS=disease-free survival; hTERT=human telomerase reverse transcriptase; NR=not report; OS=overall survival; PFS=progression-free survival; Qprc = Real-time quantitative PCR; RFS = recurrence-free survival.

Figure 2: Forest plot of included studies examining the association between telomere length and overall survival.
5.10) and patients’ age more than 60 (n = 3, HR 2.65, 95% CI, 1.22 to 5.76). The inter-study heterogeneity of all the three above subgroups decreased significantly (all $I^2 = 0$). However, we did not find significant prognostic associations between TL and CRC OS stratified by sample origin (peripheral blood or tumor tissue), patient mean/median age (< 65 years or ≥ 65 years) or sample size (< 100 or ≥ 100) (Table 2).

### DISCUSSION

#### Principal findings of this study

The results of this meta-analysis including 8 cohort studies enrolling 1622 patients showed a neutral prognostic effect of TL on CRC survival in terms of OS and DFS/RFS/PFS. Subgroup analyses found that long TL (versus short TL) was significantly associated with poor OS in studies conducted in Europe, using Southern blot to measure TL and patients’ age more than 60 years. We found no significant associations between TL and patient DFS/RFS/PFS.

#### Comparisons with previous studies

Although the results reported within the current meta-analysis did not quite agree with previous ones which showed that TL was significantly associated with patient OS. Jia et al. reported that short TL in peripheral blood leukocytes was significantly associated with poorer OS with fixed-effects model (HR 2.01, 95% CI 1.46 to 2.77) by pooling data from four studies [21]. Zhang et al. also summarized the four studies and obtained similar result [20]. These two studies, however, have limited implications for this topic for the low statistical power.

<table>
<thead>
<tr>
<th>Sample origin</th>
<th>Hazard ratio</th>
<th>95% Confidence interval</th>
<th>Degree of heterogeneity (I$^2$ statistics; %)</th>
<th>$P$-value</th>
<th>No. of included Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral blood</td>
<td>0.74</td>
<td>0.18 to 3.55</td>
<td>82.0</td>
<td>0.76</td>
<td>2</td>
</tr>
<tr>
<td>Tumor tissue</td>
<td>1.53</td>
<td>0.89 to 2.61</td>
<td>76.7</td>
<td>0.12</td>
<td>5</td>
</tr>
<tr>
<td>Study region</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Europe</td>
<td>2.73</td>
<td>1.65 to 4.52</td>
<td>0</td>
<td>&lt; 0.001</td>
<td>4</td>
</tr>
<tr>
<td>Others</td>
<td>0.70</td>
<td>0.43 to 1.12</td>
<td>82.7</td>
<td>&lt; 0.001</td>
<td>3</td>
</tr>
<tr>
<td>Mean/median age (ys)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 65</td>
<td>0.93</td>
<td>0.42 to 2.03</td>
<td>89.7</td>
<td>0.85</td>
<td>3</td>
</tr>
<tr>
<td>≥ 65</td>
<td>1.69</td>
<td>0.59 to 4.85</td>
<td>65.1</td>
<td>0.33</td>
<td>3</td>
</tr>
<tr>
<td>Sample size</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 100</td>
<td>2.19</td>
<td>0.64 to 7.48</td>
<td>81.1</td>
<td>0.21</td>
<td>3</td>
</tr>
<tr>
<td>≥ 100</td>
<td>1.04</td>
<td>0.47 to 2.30</td>
<td>86.3</td>
<td>0.92</td>
<td>4</td>
</tr>
<tr>
<td>TL detection method</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>qPCR</td>
<td>0.77</td>
<td>0.49 to 1.12</td>
<td>78.6</td>
<td>0.26</td>
<td>4</td>
</tr>
<tr>
<td>Southern blot</td>
<td>2.93</td>
<td>1.69 to 5.10</td>
<td>0</td>
<td>&lt; 0.001</td>
<td>3</td>
</tr>
<tr>
<td>Follow-up period (ms)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 60</td>
<td>1.21</td>
<td>0.50 to 2.94</td>
<td>88.1</td>
<td>0.68</td>
<td>4</td>
</tr>
<tr>
<td>≥ 60</td>
<td>2.65</td>
<td>1.22 to 5.76</td>
<td>0</td>
<td>0.01</td>
<td>3</td>
</tr>
</tbody>
</table>

Abbreviations: ms, months; TL, telomere length; ys, years.

## Table 2: Subgroup analyses based on some baseline features of included studies for overall survival
with small sample size of included studies. Another recently published study by Adam et.al. [30] also found null association between TL and cancer outcomes. However, it is not just focused on CRC and with limited subgroup analyses.

**Strengths and limitations of the study**

There are some limitations to our study. First of all, despite the largest number of studies and patients included on the association between TL and CRC survival, most were small, single-center studies with a higher risk for biases. Secondly, the small number of included studies limited further subgroup analysis and had relatively lower statistical power of the relationship between TL and CRC outcomes. Moreover, DFS, RFS and PFS were combined as the same outcome which could lead to significant heterogeneity as these outcome measures were somewhat different. Moreover, covariants among the included studies are not completely consistent. Finally, several primary selected studies or abstracts were excluded due to the unavailability of original data, which might lead to publication bias for pooled estimates.

There are a number of important strengths for our study. Firstly, we used rigorous search strategies to systematically identify all relevant studies to examine the effect of TL on CRC outcomes. Secondly, significant inter-study heterogeneity was detected in terms of characteristics of observational studies, patient selection (study region, age, tumor stage, etc.), exposure factors (TL measurement methods, cutoffs for long and short TL), therapeutic schedules and outcome reported, though several prespecified subgroup analyses and sensitivity analysis were conducted to explore the sources of heterogeneity. Still several other sources of heterogeneity could not be determined. Additionally, some other factors, such as different study design (prospective versus retrospective), tumor *KRAS/BRAF/PIK3CA* mutation status that affected the survival of CRC patients should also be attributed to some of the heterogeneity. Based on the results of subgroup analyses (Table 2), we noted that I² was significantly reduced when analyses were stratified by research region, TL detection method and follow-up period, indicating that these three factors could be part of the sources of heterogeneity. Thirdly, we used a validated scale, NOS to assess the quality of the study evidence for every cohort as was suggested by Cochrane. Fourthly, a relatively large sample size including over 1500 patients made the quantitative analysis more reliable on the association between TL and CRC prognosis. Fifthly, we evaluated each citation by cross-checked means during the process of study screening, data abstraction and quality assessment to maximally minimize selection bias, making the systematic review more objectively.

In summary, current evidence did not provide solid indication that long TL is significantly associated with improved or poor survival for patients with CRC, although the real association remains to be further confirmed by

Figure 3: Funnel plot of included studies examining the association between telomere length and overall survival.
the existing evidence. However, in some subgroups, it provides evidence that in specific population with standard TL detection method (Southern blot) or long-term follow-up (≥ 60 months), long TL may serve as a prognostic biomarker for patients with CRC. Further large sample size prospective cohort studies are warranted to determine the true relationship for some of those specific patients.

MATERIALS AND METHODS

Literature search

We developed the search strategies based on the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement [31]. PubMed, Embase and the Cochrane Library Central Register of Controlled Trials databases from inception through April 2017 were systematically searched for studies investigating the associations between TL and CRC prognosis. Detailed search strategies of the above three databases were presented in Supplementary Table 1. In summary, the following searching terms or phrases with the combinations queries with Boolean logic were used: ‘telomere’ or ‘telomeres’ or ‘telomeric’, ‘colorectal’ or ‘colonic’ or ‘rectal’, ‘cancer’ or ‘neoplas*’ or ‘carcinoma’, ‘mortality’ or ‘prognosis’ or ‘prognostic’ or ‘survival’. We limited the language of included studies only to English, as studies published in other languages were often difficult to interpret and not available for readers.

Study selection

Two investigators (W.W., L.Z. or N.Z.) evaluated the titles or abstracts through the primary literature search independently. The final included articles were cross-checked for eligibility by a third investigator (Y.Z. or Y.T.) if necessary until agreement was reached. The inclusion criteria for study eligibility were set as follows: observational (prospective or retrospective) studies reported prognostic outcomes for blood sample or tumor tissue relative TL (long versus short) in CRC patients, and studies provided the definite survival data [risk estimates such as HRs/relative risks (RRs) with 95% CIs obtained directly or estimated through other method [32]. For those overlapped prognostic data, the most recent and comprehensive one was selected for inclusion. Since the low quality of unpublished data and abstracts, we did not include these studies.

Data extraction

The study elements regarding the study design, patient characteristics, outcomes, exposure of each included study were extracted as follows: the first author and publication year, research country, study sample origin and sample size, mean/median patient age, tumor stage, treatment regimen, assay/detection method for TL, follow up period, outcome reported, adjustment factors and study quality.

Quality assessment

We applied NOS to assess the quality of each included study, which was calculated based on three major aspects of cohort studies including selection and comparability of study groups, ascertainment of the outcome of interest [33]. Two investigators scored the study quality independently (score range for cohort study 0–9), with a higher score representing better methodologic quality.

Statistical analysis

All the data were pooled using STATA software 12.0 (StataCorp LP, College Station, TX, USA). We abstracted study estimates (HRs or RRs with 95% CIs) with full adjustments from the included studies and pooled using random-effects model [34] due to the proposed high inter-study heterogeneity. An estimated HR > 1 implied a poor survival for the patient with longer TL (compared with shorter TL). Inter-study heterogeneity was assessed using F statistic and the Cochrane Q statistic, which was defined as an F > 50% and p-value < 0.10 indicating substantial heterogeneity, respectively [35]. If the potential heterogeneity existed, subgroup analyses were performed based on some of the baseline variables that the heterogeneity could attribute to.

Potential publication bias was evaluated by visual inspection of a funnel plot symmetry and by Egger’s test or Begg’s test [36, 37]. Duval’s nonparametric trim-and-fill method [38] was also applied to adjust the pooled estimates for investigating the potential effect of publication bias.

CONFLICTS OF INTEREST

The authors disclose no potential conflicts of interest.

REFERENCES


